You are here: Industry Insights > Jazz Pharmaceuticals

News List

Jazz Pharmaceuticals Submits MAA to European Medicines Agency for Solriamfetol americanpharmaceuticalreview
November 10, 2018
Jazz Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, as a treatment to improve wakefulness and reduce ex
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepi biospace
March 05, 2018
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has accepted a standard review
ImmunoGen and Jazz collaborate to develop and market ADC products pharmaceutical-technology
August 31, 2017
ImmunoGen has entered a collaboration and option agreement to grant exclusive worldwide rights to Jazz Pharmaceuticals for the development and commercialisation of two haematology-related antibody-drug conjugate (ADC) candidates, IMGN779 and IMGN632.
Jazz Pharmaceuticals submits FDA application for leukaemia treatment europeanpharmaceuticalreview
April 10, 2017
Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos (cytarabine and daunorubicin) liposome for injection.
Jazz Pharmaceuticals Reaches Settlement with Hikma Pharmaceuticals Related to Xyrem Patent Litigatio americanpharmaceuticalreview
April 07, 2017
Jazz Pharmaceuticals announced that certain of its subsidiaries have entered into agreements with Hikma Pharmaceuticals PLC and related entities ("Hikma") resolving patent litigation related to Xyrem® (sodium oxybate) oral solution.
Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an I drugs.com
April 06, 2017
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced the completion on March 31, 2017 of a rolling submission of a New Drug Application (NDA)...
First patient enrolled in Phase II study evaluating JZP-110 for excessive sleepiness in Parkinson's cphi-online
February 14, 2017
JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.

Previous page 1 2 Next page